Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies

• Status: Completed
• Trial end date: 2019-09-10
• Target enrollment: 0
• Participant gender: All

Summary

Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft. Patients of the Control group take only standard antimicrobial prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. Laboratory tests are performed on peripheral blood samples.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azienda Ospedaliero, Universitaria Pisana
• Treatments: Acyclovir; Fluconazole; Levofloxacin; Ofloxacin; Zinc; Zinc Sulfate

Criteria

Inclusion Criteria:

• eligibility to stem cell transplantation

Exclusion Criteria:

• allergy to Zinc

• copper deficiency or Wilson's syndrome

• patients who admit zinc assumption in other drugs